Abstract
Although the MAPK pathway is aberrantly activated in triple-negative breast cancers (TNBCs), the clinical outcome of MEK-targeted therapy is still poo......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
